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The delivery of cardiovascular care has undergone dra- 
matic hanges. New technologies, therapies and systems for 
health care delivery have emerged and have done so largely 
through cooperative efforts of our profession and industry. 
These developments have benefited our profession, the 
industry and, most importantly, our patients. Further devel- 
opment will require continued cooperative fforts. Yet 
such efforts are threatened by increasing concerns regard- 
ing the motives of those involved (l-3). Enormous amounts 
of money are involved in health care (approximately 12% of 
our gross national product or $550 billion in 1988). Physi- 
cians largely control how this money is allocated. Therefore 
it is not surprising that industry devotes much of its market- 
ing to physicians to influence prescribing habits and pur- 
chase of their products. Physicians and their patients benefit 
from these activities when the relation between physicians 
and industry is based on ethical principles and mutual 
respect. 
Ethical behavior ultimately isan individual decision but 
it must be appreciated that it is the perception by patients, 
health policy makers, the media, and others, of our ethical or 
unethical behavior that will determine society’s response. 
The cardiovascular community (physicians, industry, insti- 
tutions and organizations) has a special obligation to help 
define the boundaries ofethical behavior in their relations. 
A guiding principle for physicians must be that their deci- 
sions about patient care are determined by the health needs 
of the patient and not based on inappropriate monetary, 
scientific or academic gains. Physicians must not be influ- 
enced by any incentives that would cause them to act in a 
manner contrary to their best professional judgment. What 
follows are guidelines to assist hose who must make deci- 




Much of our educational ctivity is fin 
by industry. In general this has been ben 
education, and continued support for th 
be encouraged. However, the primary objective of such 
programs must be educational. Programs should not be used 
to promote the products of the sponsor. Selection of topics 
and discussants shoul be determined by the medical direc- 
tor of the program or the stalf to which the presentation is to 
be made. Honoraria for faculty participants should be in 
keeping with the participants’ contributions. Honoraria nd 
inducements foraudience attendees shouid not be accepted. 
payment of expenses for attendees may be acceptable in
situations consistent with educational objectives with appro- 
priate accreditation. For example, appropriate situations are 
those in which the attendees are faculty participants and in 
which the program control and selection of attendees i
determined by physicians, without restriction by industry. 
Lavish entertainment a d gifts are inappropriate. Expenses 
should not be paid or reimbursed for spouses or guests of 
attendees. Provision of meals as part of a meeting is an 
acceptable practice. Speakers sponsored by industry should 
be identified in the program or at the time of the presenta- 
tion. 
5. Industry-initiated Conferences 
Particular attention should be given to conferences orga- 
nized and conducted directly by industry. Physicians partic- 
ipating as faculty in such meetings have an obligation to 
present scientifically balanced information. They are fre- 
quently well recognized leaders in the field whose recom- 
mendations are readily accepted. Their comments must not 
be subject to approval or censored by the sponsoring com- 
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of that support is appropriate. 
that these programs are organiz 
as educational events. 
responsible for selectio 
expenses. 
iscussants. Attend- 
. Industry and Trainees 
Previous comments pertaking to physicians and their 
relation to the health care industry also apply to physicians 
in training. However, the latter may be particularly suscep- 
tible to marketing efforts. Supervising physicians, particu- 
larly directors of training programs, hou!d take an active 
role to assure that ethical principles are adhered to by all 
parties. Pharmaceutical ompanies frequently provide meals 
at educational programs conducted for physicians in train- 
ing. presentatives of the companies are often permitted to 
brie present product iaformatio~ at these conferences. 
This is an acceptable practice if all pharmaceutical ompa- 
ies that wish to participate have equal oppo~un~ties o do 
so and if supervising physicians are in attendance to ensure 
a balanced presentation. The direct personal cceptance d 
meals or entertainment at functions without a signific,ant 
educational component is discouraged. 
cian. Industry views these ite 
cians to use a ce 
receive financial incentives such as fre 
or direct cash payment if they prescribe 
These studies can be an important part of the continuing 
monly provided and are acceptable if 
s’ services. These are ac- 
ceptable practice provided the fee is CC? ensurate with the 
services performed. 
et ~e~~re~ for s. These are common prac- 
tice. Individuals are usually paid for participation i  the 
focus group, which is an acceptable practice if physicians’ 
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comments are uninfluenced by the sponsoring organization 
and honoraria are in keeping with the service provided. 
General guidelines for giving and accepting gifts. Any- 
thing given to physicians by industry should not be 1) a 
reward for selecting a specific product; 2) an incentive for 
selecting a product other than on scientific grounds (educa- 
tional material about a product is an acceptable form of 
incentive); 3) out of proportion to a need, for example, 
foreign trips to view a facility or equipment. The recommen- 
dations of the Royal College of Physicians that acceptable 
gifts are those that are “inexpensive and related to the 
practice of medicine” are appropriate: “. . . a useful crite- 
rion of acceptability may be-would you be willing to have 
these anangements generally known?” (4). Physicians 
should not accept or demand lavish gifts such as dinner or 
ente~ainment to discuss a ~presentat~ve’s pr~uct. 
The economic ph~osophy of our society not only sup 
ports but encourages individual economic investment. Phy_ 
sician participation in the ownership ofhealth care facilities, 
such as imaging centers and mobile cardiac ~thete~tio~ 
laboratories, i  increasing. Although currently legal, there is 
considerable d bate as to whether physician ownership of 
facilities to which they refer patients i ethical. The potential 
for unethical behavior or the appearance of a conflict of 
interest occurs whenever physici~s gain financially from 
their patients* expenses for services the physician orders but 
does not provide directly. It appears that patie& ;!enerally 
are unaware of their physician’s involvement inthrse facil- 
ities. Physician involvement in such activities may be ac- 
ceptable if these activities clearly improve patient care 
above that available in the community. It is mandatory that 
physicians disclose to their patients heir financial interest in 
such facilities. 
U~o~unately health care facilities are often developed in
areas that already have adequate facilities. The introduction 
of new facilities without evidence of need will increase 
medical care costs-this in itself is unethical. 
A. institutions 
Hospitals depend on physicians tomaintain an adequate 
patient base. Today, a large number of hospital beds are 
unfilled and competition for patient revenue is intense. 
Increasingly, instiMons are awarding incentives to physi- 
cians in order to attract patients. Physicians hould deter- 
mine where to refer their patients on the basis of the quality 
of care provided by an institution regardless of financial 
incentives to the physician. 
As a result of the intense competition for patient revenue, 
physicians may be subject o pressures from institutions to 
increase such revenue. This is pa~icu~arly true for physi- 
cians salaried by or under contract to institutions such as 
managed care facilities and faculty practice plans. The 
practice of publiciy comparing physicians by revenue gener- 
ated, hospital revenue saved or procedures ordered is often 
designed to enhance profits, with a d~sreg~d forthe quality 
of patient care. institutions sbo~~d beconcerted p~ma~ly 
with the quality of care provided by their physicians. Con- 
versely, physicians must have an awareness of the ~~ancial 
pressures institutions are under and avoid unnecessary over- 
or underutilization f resources. Physicians have an obliga- 
tion to cooperate with administ~tors in determining cost- 
effective strategies for their institution. 
B. Organizatims 
Physicians are generally members ofseveral professional 
o~anizations orsocieties. Physicians inpositions that io~u- 
ence the activities or decisions of these organizations must 
avoid any potential conflict of interest. Organizations should 
insist on and physicians agree to disclosure of any arrange- 
ments they or their immediate families have with the corpo- 
rate sector that could lead to conflicts of interest, for 
example, the holding of stock, equity interests, directorships 
or consulting relations with a company. Obviously physi- 
cians must avoid pa~icipating in decisions that tiect com- 
panies in which they have financial arrangements. These 
precepts do not imply that physicians hould not have 
financial relations with indust~ but that hese relations must 
be revealed before situations occur in which there is poten- 
tial conflict of interest. 
Physicians are indispensable to the health care research 
conducted by industry. The maintenance of scientific integ- 
rity by all parties in these endeavors i essential. ~ndust~ 
must utilize proper safe;, qrds that assure that they do not 
influence results of &E “ponsored research. Physicians 
should not have a~angements with iRdust~, such as stock 
or equity interests, that would result in financial advantage 
based on the results of the study. 
The use of inside information for persona1 gain by physi- 
cians involved in research or data review is both illegal and 
unethical. 
When participating as an investigator in industry- 
sponsored single investigator clinical research or mult~ce~te~ 
trials the investigator I) should not be given personal incen- 
tive payments or rewards for accomplishing a research 
protocol; 2) should not hold direct significant financial inter- 
JACC Vol. 16, Ho. 1 
July 1m 1-36 
ing as faculty members in such meetings 
obligation to be sure that unbiased ~nformati 
B. ~~y~~ci~~-~~iti~t~d ~~~~~~~~s. Prog 
ganized and conducted ~~~~ar~~y as edM~at~o~a~ 
Industry should not specify speakers or topics. 
should pay tuition and travel expenses. 
C. ~~dffst~ nnd tmi~ees. Supe~isi~g of ~bys~ciaas, par- 
titularly ejectors of tra~~~~~ g~rns, boa~d take an active 
role in assuring that ethical p~n~i~~es ar  adhered to by all 
tions should be subject o peer eview. 
Acceptable gifts are those that are “inexpensive and 
related to the practice of medicine . . .-a useful criterion of 
acceptability may be-would you be willing to have these 
arrangements generally known?” (4). 
5. ~~ys~c~~ ownership of wealth care ~~ci~~ties 
Such ownership is acceptable if it clearly improves pa- 
tient care above that which is available in the community. 
Disclosure of ownership to patients i  mandatory. 
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It is suggested that hese case studies be discussed ina group 
setting in the light of the principles embodied in the 21st 
Bethesda Conference. This would facilitate the teaching of 
ethics to fellows, ~sidents and students and would also 
provide the basis for peer discussion of ethical issues in 
cardiovascular medicine. 
You are on the pharmacy committee for your hospital. 
The pharmacy has decided to stock only one nitrate patch 
and has asked the committee for recommendations. You 
own stock in one of the competing companies. 
1. Should you exclude yourself from the decision? 
2. Should you exclude yourself i you do not have stock in 
the company but your wife does? 
Case Study 2 
A 42 year otd, HIV positive, homosexual man with angina 
has had increasing chest discomfort with activity despite 
Isordil isosorbide dinitrate, 40 mg three times daily, pro- 
panalol, 60 mg every 6 h, and diltiaxem, 60 mg every 6 h. On 
phi&al e~inati~ he has prominent cervical iymphade- 
no~thy and inguinal lymphadenopathy but has never had an 
opportunistic infection. 
1. Should this patient undergo cardiac catheterization in 
preparation for a revascularixation procedure? 
Case Study 3 
An 84 year old woman presents with an acute inferior wall 
myocardial infarction complicated by ventricular arrhyth- 
mias. She is a widow but has two married children living in 
other pa& of the county. She had been self-s~cient and 
had hypertension a d diabetes that had been well controlled 
medically, was a regular churchgoer and has several ctose 
friends. She is initially treated in the coronary care unit, but 
on the 3rd day of hospitalization developed sudden onset of 
congestive heart failure, a neJv heart mu~ur, pulmonary 
edema nd cardiogenic shock. 
1. How should the attending physician proceed from here? 
Case Study 4 
You are responsible for a monthly grand rounds at your 
reunify hospital. A dig representative asks if his com- 
pany can provide aspeaker to talk about “~y~~e~sio~,” an 
area in which they have just released a new drug. 
1. Is this acceptable? 
2. Are you obligated tofind out more about he presentation 
from the speaker? 
3. Should you specify that the antihype~ensive drug not be 
mentioned except as a class of drug? 
4. May the drug company provide refreshments? 
Case Study 5 
Dr. Smith is active in ~oro~ary angioplasty a 
research. He has conceived plans for a new 
coronary artery recanalization, for which he has sought a 
patent. A manufacturer expresses interest in the concept, 
offers to do the technical development and offers financial 
super so that Dr. Smi can conduct some of the requisite 
anhmal studies and ultimately some of the clinical studies. In 
exchange, an exclusive license is sought and Dr. Smith is 
offered the option of selecting one of three plans: 1) usual 
licensing and royalty fees, 2) a consultation fee ($50,000 per 
year) and reduced licensing and royalty fees, or 3) stock 
equal to 10% of the outstanding stock of the ~orn~ny, 
1. Is it proper for Dr. Smith to select any one of these plans? 
2. Are there other factors to which he must be sensitive as 
’ well? 
Case Study 6 
A 25 year old intravenous drug abuser is brought from the 
county jail because of a iligh fever lasting 3 days. On 
physical examination he has all the signs of severe mitral 
insu~~iency. IIe had t~cuspid endo~ar~tis 2 years earlier, 
He last used intravenous drugs 1 day before being arrested. 
The patient is tachypneic with bibasilar rales, a grade 316 
pansystolic murmur at the apex and S3 and S, gallops. After 
administration f furosemide and digoxin, the patient is less 
tachypneic, but still has a heart rate of 100 beats/mitt. 
A~e~~d suction with ca~t~~~l does not substantially 
improve the patient’s symptoms. We is comfortable atrest 
but he is short of breath after walking two blocks or up one 
flight of stairs. 
ana 
3. If you are the traine 
that you are sponsore 
irector 
has no history of cardiac disease or 
stable vital signs, no heart failure 
3 mm anterior ST elevation i ECG leads V, to V 
and benefits of thrombolytic therapy are ex 
and he understands. He is very fearful of st 
remains table and he has no objective or subjective signs of 
heart failure. He is told that he is to be admitted to the 
coronary care unit. He does not want o stay in the hospital. 
He feels well and wants to return to his hotel room. 
I. How should the health care team proceed? 
2. What ethical issues are involved? 
3. Was the decision ot to give thrombolysis well founded? 
Case study 9 
Baby girl Roe, a 3.2 kg term infant, is transferred toyour 
hospital at 36 h of age because of cyanosis and hypotension. 
Echocardiographic examination reveals hypoplastic left 
heart syndrome. An intravenous infusion of prostaglandin E 
stabilizes her condition. She has no abnormalities other than 
her heart conditions. 
er 38 year old mother had no 
prior pregnancies and was previously infertile. She under- 
went a tubal igation shortly after delivery. The mother has 
medical insurance that will lapse for the infant unless the 
survivors are usua 
and there are frequent blood tests 
coronary disease, infection, rejection and need for retrans- 
plantation. The cost of necessary drug treatment is about 
I. How would you discuss these issues with this family? 
Case Siudy 10 
hite sits on the data nd safety monitoring board of 
nter clinical trial sponsored by the National Insti- 
tutes of Health (NH), and in this capacity, at 6 month 
intervals, he sees the confidential interim results of this 
randomized double-blind trial. The study is assessing the 
clinical effectiveness of a drug from a new class of lipid- 
lowering drugs. A company that has another drug 
class wants to organize and support aclinical trial 
r. White to participate in tht desi 
its steering committee and ulti 
participate asone of the physicians engaged inthe trial. 
1. Should Dr. White proceed? 
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case Study If 
In addition to his teaching and clinical responsibilities, 
Dr. Jones is engaged in NE&funded research involving a 
new class of drugs for the management of acute myocardial 
infarction. A pharmaceutical house offers additional re- 
search super to cover the cost of a technician and supplies 
so that its drug can be added to the various ongoing studies. 
The company asks Dr. Jones to serve twice a year as a 
consultant for 1 day, at a $5,000 fee on each occasion, to 
apprise them of the latest developments in his research and 
in his area of research. De is also invited to join the list of 
speakers whose xpenses and Honda for lecturing on the 
management of acute myocardial infarction and the role of 
this class of drugs will be reimbursed to the host medical 
group by the company. 
I. Shoutd Dr. Jones proceed? 
2. Are there any terms or issues that need clarification or
limits that need to be placed? 
Case Study 12 
You are a p~ctic~g c~diolo~st and are offered an all 
expense-paid trip for you and your wife to a meeting in the 
Bahamas. The program is sponsored by a well-known med- 
ical school, and the faculty are experts in the field. The 




Should you accept he trip? 
Does it make a difference if your spouse is not provided 
airfare? 
Does it make a difference if the invitation comes from the 
director of cardiology at the sponsoring institution? 
Case Study 13 
A 30 year old intravenous drug abuser with infective 
endocarditis of the mitral valve, which resulted in mitral 
valve replacement 2 years earlier, now enters the hospital 
with a fever of 103°F and a new grade 216 diastolic mu~ur 
of aortic regurgitation. His blood pressure is 160/30 mm Hg, 
and he has all the peripheral signs of aortic regurgitation. 
The patient isknown to still use intravenous drugs, and three 
blood cultures indicated streptococcus enterococcus. 
1. Should the patient have aortic valve reptacement? 
Case Study 14 
A 74 year dd patient presents with an out of hospital 
cardiac arrest. He was resuscitated byan observer of the 
JACC Vol. 16, No. 1 
July 1990:1-36 
event, and within 12 h be is lucid, without neurology deceit. 
His past history includes known metastatic cancer of the 
colon. He also underwent coronary artery bypass grafting 
some 10 years ago. He desires all treatment to maintain 
survival. 
1. Is he a candidate for coronary angiog~phy and repeat 
coronary artery bypass grafting? 
A 62 year old patient is referred to you by a ~ardiovas- 
cular surgeon on the staff of your hospital for a second 
opinion on the need for coronary bypass surgery. The 
patient has led a sedentary life as a banker. He is mildly 
hy~~ensive, obese, weighs 90 kg and is only 1.79 m tall. He 
had smoked two packs of ~igare~es 3 day until 2 weeks 
previously when he had terminated the habit. In addition, he 
usually had one to two alcoholic drinks before dinner 
nightly. He had experienced new onset of effort angina 6 
weeks previously. A stress test confirmed the diagnosis, 
with pain compatible with angina, and I to 1.5 mm ~o~~o~ta~ 
ST segment depression developing in EC6 leads II, III, 
aVF, and Vg and V, at the end of the second stage of the 
Bruce protocol. Coronary arteriograms demonstrated an 
80% stenosis of the midportion of the right coronary artery, 
a 50% to 60% stenosis of the mid~~ion of the left circum- 
flex artery and a 3Q% steoos~s of the mid~~ion of the left 
anterior descending artery. Ejection fraction was 60%. His 
cholesterol level was 236 mg/dl, triglycerides 360 mg/dl and 
high density lipoprotein cholesterol 34 mgldl. The patient’s 
pain was controlled by a long-acting nitroglycerin prepara- 
tion and a bed-blocker. The blood pressure was also con- 
trolled and the patient pa~ici~ted in a regular exercise 
program. He lost 2.25 kg of weight over a 3 week interval. A
repeat stress test again showed ischemic changes developing 
at 5 min and 30 s on the Bruce protocol. The patient had no 
pain during the procedure. The patient lives in a community 
80 km from a medical center. The ~ospit~ inthat community 
has a cardiovascular c theter laboratory but no facilities for 
cardiovascular surgery. Patients requiring surgery are re- 
ferred to the hospital in which you practice, usually to the 
surgeon who had referred the patient to you. The patient had 
been referred to that surgeon but had requested a second 
opinion as to whether the surgery was necessary. The 
surgeon asks you to see the patient. 
1. What is your assessment of the need for bypass urgery 
or percutaneous tr~s~umin~ an~oplasty? 
2. How do you proceed? 
